Mitsubishi Tanabe Incurs 6 Billion Yen Operating Loss as Flu Vaccine Project Dropped in US

Mitsubishi Tanabe Pharma posted an operating loss of 6 billion yen in FY2019 as it booked an impairment loss of 24 billion yen after its Canadian subsidiary discontinued the development of its seasonal influenza vaccine MT-2271 in the US. Its...read more